Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study Evaluating Ibuprofen 600 mg Extended Release (ER) For Dental Pain

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00913627
Recruitment Status : Completed
First Posted : June 4, 2009
Results First Posted : March 22, 2018
Last Update Posted : March 22, 2018
Sponsor:
Information provided by (Responsible Party):
Pfizer

Brief Summary:
The purpose of this study is to assess the efficacy and safety of a single dose of an ibuprofen 600 mg extended release formulation in post-operative dental pain. There is concern that the manufacturing process may affect the performance characteristics of the selected prototype. Therefore, two formulations of this prototype manufactured by two different processes, [roller compaction] and [wet granulation] will be included in this study. The preferred prototype manufactured by two different methods will be compared to placebo and each other. This study will also characterize the pharmacokinetic/pharmacodynamic relationship with these formulations.

Condition or disease Intervention/treatment Phase
Pain Drug: ibuprofen Drug: naproxen Drug: Placebo Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 196 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: Ibuprofen 600 Mg Extended Release (er) Single-dose Dental Pain Study
Actual Study Start Date : May 7, 2009
Actual Primary Completion Date : August 1, 2009
Actual Study Completion Date : August 5, 2009

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: 1
1 x 600 mg ibuprofen IR/ER-roller compaction caplet
Drug: ibuprofen
Experimental: 2
1 x 600 mg ibuprofen IR/ER-Wet granulation caplet
Drug: ibuprofen
Active Comparator: 3
1x 220 mg naproxen sodium (Aleve caplet)
Drug: naproxen
Placebo Comparator: 4
1 x placebo caplet
Drug: Placebo



Primary Outcome Measures :
  1. Time-weighted Sum of Pain Intensity Difference Score From 0 to 12 Hours (SPID 0-12) [ Time Frame: Baseline (0 hour) to 12 hours post dose ]
    Pain intensity difference (PID) score based on 4-point categorical pain intensity rating scale. Participants asked, "How much pain do you have at this time?" Range of scale: None (0), Mild (1), Moderate (2), Severe (3). SPID derived by adding the time-weighted sums of PID scores over the time interval. Scores could range from -12 to 36 where higher positive values indicated improvement (decrease in pain intensity).

  2. Time-weighted Sum of Pain Intensity Difference Score From 8 to 12 Hours (SPID 8-12) [ Time Frame: 8 to 12 hours post dose ]
    PID score based on 4-point categorical pain intensity rating scale. Participants asked, "How much pain do you have at this time?" Range of scale: None (0), Mild (1), Moderate (2), Severe (3). SPID score derived by adding the time-weighted sums of PID scores over the time interval. Scores could range from -4 to 12 where higher positive values indicated improvement (decrease in pain intensity).


Secondary Outcome Measures :
  1. Time to First Perceptible Pain Relief [ Time Frame: Baseline to 6 hours ]
    Time to first perceptible relief (confirmed by meaningful relief) was defined as the elapsed time from dosing until the participant depresses the first stopwatch labelled "first perceptible relief", if the participant also depressed the second stopwatch labelled as "meaningful relief" by 6 hours. If the confirmation was not achieved, the participant was censored at 6 hours. Perceptible relief defined as when participant first begins to feel any pain relieving effect whatsoever of the drug. Does not necessarily mean the participant feels completely better, but when the participant first feels any difference in the pain he/she has currently.

  2. Time to Treatment Failure [ Time Frame: Baseline to 24 hours ]
    Time to first rescue medication or discontinuation due to lack of efficacy

  3. Percentage of Participants With Treatment Failure [ Time Frame: 8, 9, 10, 11, and 12 hours ]
    Treatment failure defined as use of rescue medication or discontinuation due to lack of efficacy.

  4. Time-weighted Sum of Pain Intensity Difference From 0 to 4 Hours (SPID 0-4) and 4 to 8 Hours (SPID 4-8) [ Time Frame: 0 to 4 hours and 4 to 8 hours ]
    Time-weighted sum of PID score. PID based on 4-point categorical pain intensity rating scale. Participants asked, "How much pain do you have at this time?" Range of scale: None (0), Mild (1), Moderate (2), Severe (3). SPID score derived by adding the time-weighted sums of PID scores over the time interval. Scores could range from -4 to 12 where higher positive values indicated improvement (decrease in pain intensity).

  5. Time-weighted Sum of Pain Relief and Pain Intensity Difference Scores (SPRID) [ Time Frame: 0 to 4 hours, 4 to 8 hours, 8 to 12 hours, and 0 to 12 hours ]
    Time-weighted sum of PRID score where PRID=PID+PR. PID: 4-point categorical pain intensity difference scale, 0 (none) to 3 (severe), score derived by subtracting postdose score from baseline, ranged from -1 to 3. Baseline pain intensity score of at least 2 required for enrollment. Higher positive PID values = improvement. PR: 5-point categorical pain relief scale None (0), A Little (1), Some (2), A Lot (3) or Complete (4). SPRID 0-4, SPRID 4-8, and SRID 8-12 scores ranged from -4 to 28, SPRID 0-12 ranged from -12 to 84, higher scores = greater improvement.

  6. Time-weighted Sum of Pain Relief Scores (TOTPAR) [ Time Frame: 0 to 4 hours, 4 to 8 hours, 8 to 12 hours, and 0 to 12 hours ]
    TOTPAR based on 5-point categorical pain relief scale. Participants asked, "How much relief do you have from your starting pain?" Range of scale: None (0), A Little (1), Some (2), A Lot (3) or Complete (4). Higher scores indicated improvement (better pain relief). For time-weighted sum of pain relief scores from 0 to 4 hours (TOTPAR 0-4), from 4 to 8 hours (TOTPAR 4-8), and from 8 to 12 hours (TOTPAR 8-12): range of scores 0 (worst) to 16 (best). TOTPAR 0-12 range of scores 0 (worst) to 48 (best).

  7. Percentage of Participants Achieving First Perceptible Relief Confirmed by Meaningful Relief [ Time Frame: 15, 30, 45, 60, 90, and 120 minutes and every 60 minutes up to 360 minutes ]
    The elapsed time from dosing until the participant indicated first perceptible relief, provided the participant also indicated achieving meaningful relief. Perceptible relief defined as when participant first begins to feel any pain-relieving effect whatsoever of the drug. Does not necessarily mean the participant feels completely better, but when the participant first feels any difference in the pain he/she currently has now.

  8. Time to Meaningful Pain Relief [ Time Frame: Baseline to 6 hours ]
    Participants evaluated the time to meaningful relief by depressing a second stopwatch at the moment they first began to experience meaningful relief, defined as relief from the pain that is considered meaningful to the participant.

  9. Percentage of Participants Achieving Meaningful Pain Relief [ Time Frame: 15, 30, 45, 60, 90, and 120 minutes and every 60 minutes up to 360 minutes ]
    Participants evaluated the time to first perceptible pain relief by depressing a stopwatch at the moment they first began to experience perceptible relief and the time to meaningful relief by depressing a second stopwatch at the moment they first began to experience meaningful relief defined as relief from the pain that is considered meaningful to the participant.

  10. Participant Global Evaluation of Study Medication at 12 Hours [ Time Frame: 12 hours ]
    Participant rated global evaluation of study medication; results reported by evaluation categories and included very poor (0), poor (1), fair (2), good (3), very good (4), and excellent (5).

  11. Participant Global Evaluation of Study Medication at 24 Hours [ Time Frame: 24 hours ]
    Participant rated global evaluation of study medication; results reported by evaluation categories and included very poor (0), poor (1), fair (2), good (3), very good (4), and excellent (5).

  12. Pain Intensity Difference (PID) Score [ Time Frame: 15, 30, 45, 60, 90 minutes and 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 16, and 24 hours ]
    PID based on 4-point categorical pain intensity rating scale. Participants asked, "How much pain do you have at this time?" Range of scale: None (0), Mild (1), Moderate (2), Severe (3). PID score derived by subtracting postdose score from baseline score and could range from -1 to 3. A baseline pain intensity score of at least 2 was required for study enrollment. Higher positive PID values indicated greater improvement (decrease in pain intensity).

  13. Pain Relief (PR) Score [ Time Frame: 15, 30, 45, 60, 90 minutes and 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 16, and 24 hours ]
    PR score based on 5-point categorical pain relief scale. Participants asked, "How much relief do you have from your starting pain?" Range of scale: None [0], A Little [1], Some [2], A Lot [3] or Complete [4]. Higher scores indicated improvement (better pain relief).

  14. Pain Relief Combined With Pain Intensity Difference (PRID) Score [ Time Frame: 15, 30, 45, 60, 90 minutes and 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 16, and 24 hours ]
    PRID=PID+PR, where PID: 4-point categorical pain intensity difference scale, 0 (none) to 3 (severe), score derived by subtracting postdose score from baseline and could range from -1 to 3. Baseline pain intensity score of at least 2 was required for study enrollment. Higher positive PID values indicated improvement. PR: 5-point categorical pain relief scale (None [0], A Little [1], Some [2], A Lot [3], Complete [4]). PRID score could range from -1 to 7 where higher scores indicated better pain relief and decrease in pain intensity.

  15. Peak Pain Relief Score [ Time Frame: Baseline to 12 hours ]
    Maximum PR score over the scheduled pain relief assessments. PR score based on 5-point categorical pain relief scale. Participants asked, "How much relief do you have from your starting pain?" Range of scale: None (0), A Little (1), Some (2), A Lot (3) or Complete (4). Higher scores indicated improvement (better pain relief).



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   16 Years to 40 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

INCLUSION CRITERIA:

  • Males and females 16 to 40 years of age.
  • Outpatients who undergo surgical extraction of 1-2 third molars, one of which must be a partial or full bony mandibular impaction and have moderate to severe post-operative pain (confirmed by a VAS score of at least 50 mm on a 100 mm VAS) following surgical extraction;
  • Use of only the following preoperative medication(s)/anesthetic(s): short-acting local anesthetic (mepivacaine or lidocaine) with or without vasoconstrictor, nitrous oxide, and/or midazolam;
  • Reliable, cooperative, and of adequate intelligence to record the requested information on the analgesic questionnaire form;
  • Examined by the attending dentist or physician and medically cleared to participate in the study;
  • In general good health and have no contraindications to the study medication.

Exclusion Criteria:

EXCLUSION CRITERIA:

  • Pregnancy, as verified by a urine-based pregnancy test, or breast feeding;
  • Presence of a serious medical condition (e.g., poorly controlled hypertension, poorly controlled diabetes, significantly impaired cardiac, renal or hepatic function, poorly-controlled hyper- or hypothyroidism);
  • Use of a prescription or nonprescription drug with which the administration of ibuprofen or any other NSAID is contraindicated;
  • Use of a bisphosphonate (e.g., risedronate [Actonel], alendronate [Fosamax], or ibandronate [Boniva]) in the past 5-years;
  • Acute localized dentalveolar infection at the time of surgery that could confound the post-surgical evaluation;
  • Females who are of child-bearing potential, or post-menopausal for less than 2 years and not using a medically approved method of contraception (i.e., oral, transdermal, or implanted contraceptives, intrauterine device, diaphragm, condom, abstinence, or surgical sterility), or females who test positive on a urine-based pregnancy test;
  • Presence or history (within 2 years of enrollment) of bleeding disorder(s) or peptic ulcer disease;
  • History of alcoholism (i.e., on average, consumes 3 or more alcoholic drinks per day) or substance abuse within the last year, or is currently abusing alcohol or other mood-altering drugs (e.g., cannabis). Patients who are taking CNS or other psychotropic drugs (including St. John's Wort, or any other nutritional supplement known to have psychotropic effects) may be enrolled if they have been on stable doses of medication for at least 2 months, will maintain this dose throughout the study, and their condition is judged by the Principal Investigator to be well-controlled;
  • Habituation to analgesic drugs (i.e., routine use of oral analgesics 5 or more times per week)
  • History of allergic reaction (e.g., asthma, rhinitis, swelling, shock, or hives) to ibuprofen, naproxen, aspirin, or to any other NSAID; or to codeine, hydrocodone, or acetaminophen, or to their combinations;
  • Prior use of any type of analgesic or NSAID five half-lives of that drug or less before taking the first dose of study medication, except for pre-anesthetic medication and anesthesia for the procedure;
  • Ingestion of any caffeine-containing beverages, chocolate, or alcohol 4 hours or less before taking the first dose of study medication;
  • The subject has taken an investigational product or participated in an investigational trial within 30 days of study enrollment;
  • The subject has previously participated in this study;
  • The subject is a member of the study site staff directly involved with the study, an employee of the Sponsor, or a relative of study site personnel directly involved with the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00913627


Locations
Layout table for location information
United States, Utah
Jean Brown Research Center
Salt Lake City, Utah, United States, 84124
Sponsors and Collaborators
Pfizer
Investigators
Layout table for investigator information
Study Director: Pfizer CT.gov Call Center Pfizer
Additional Information:
Layout table for additonal information
Responsible Party: Pfizer
ClinicalTrials.gov Identifier: NCT00913627    
Other Study ID Numbers: AK-09-07
B4371001 ( Other Identifier: Alias Study Number )
First Posted: June 4, 2009    Key Record Dates
Results First Posted: March 22, 2018
Last Update Posted: March 22, 2018
Last Verified: February 2018
Keywords provided by Pfizer:
Extended-release
ibuprofen
Additional relevant MeSH terms:
Layout table for MeSH terms
Toothache
Tooth Diseases
Stomatognathic Diseases
Facial Pain
Pain
Neurologic Manifestations
Ibuprofen
Naproxen
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Gout Suppressants